A group of 29 nonproliferation supporters sent a letter to President Biden asking that he withhold federal support for a proposed pilot plant for recycling spent nuclear fuel to be built by the Wisconsin-based fusion tech company SHINE Technologies. The experts further asked that Biden “discourage” the Nuclear Regulatory Commission from licensing the plant, claiming it would extract enough weapons-grade plutonium to build 100 atomic bombs a year.

Orano and SHINE Technologies have agreed to cooperate in the development of a pilot plant capable of recycling used nuclear fuel from light water reactors on a commercial scale. In announcing the signing of a memorandum of understanding on Thursday, the companies said the selection of a site for the pilot U.S. facility is expected by the end of this year.

Waste disposal start-up Deep Isolation and fusion tech company SHINE Technologies have announced the completion of a collaborative study assessing the costs of disposing of radioactive byproducts from a pilot spent nuclear fuel recycling facility.

According to the Council on Radionuclides and Radiopharmaceuticals, more than 82,000 nuclear imaging procedures using nuclear medicine are performed throughout the world every day. To administer these vital medical procedures, radiopharmaceutical companies and hospitals rely on a handful of producers of medical radioisotopes.

The Gateway for Accelerated Innovation in Nuclear (GAIN) announced December 19 that seven firms will get vouchers to access the nuclear research facilities and expertise of the national laboratory complex in the first round of fiscal year awards. Each company is paired with one or more national laboratories to work on concepts from advanced reactor fueling to fuel recycling to climate forecasting.

Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.

Fusion systems company SHINE Technologies has notified the Nuclear Regulatory Commission that it intends to submit a license application to build and operate a pilot used nuclear fuel recycling facility.

SHINE Technologies, a Wisconsin-based medical isotopes and fusion technology company, announced today that it has demonstrated clearly visible Cherenkov radiation produced by fusion for what is believed to be the first time in history. Cherenkov radiation is the characteristic blue glow typically seen in underwater fission reactions.

Fusion tech company SHINE Technologies announced that it is opening the largest facility in North America dedicated to the production of non-carrier-added lutetium-177, a medical isotope used in targeted cancer therapies.

Fusion development company SHINE Technologies announced that it will begin offering radiation effects testing in a dedicated facility on the company’s Janesville, Wis., campus later this year. SHINE will use high-energy fusion neutrons to test mission-critical components that are susceptible to radiation-harsh environments on behalf of its aerospace and defense customers.

NorthStar Medical Radioisotopes has completed construction and all equipment installation at its new facility in Beloit, Wis., to produce the medical radioisotope molybdenum-99 without the use of high-enriched uranium, the Department of Energy’s National Nuclear Security Administration announced last week.

SHINE Europe, a subsidiary of Wisconsin-based SHINE Technologies, will work with the Netherlands’ University Medical Center Groningen (UMCG) and Delft University of Technology (TU Delft) to produce a variety of terbium isotopes for use in nuclear medicine under a grant proposal approved by the Dutch government on October 17.

SHINE Technologies, the Janesville, Wis.–based producer of medical radioisotopes, announced that it has submitted a drug master file (DMF) with the U.S. Food and Drug Administration for non-carrier-added (n.c.a.) lutetium-177 chloride, a radiopharmaceutical used for the treatment of cancer.

The Nuclear Regulatory Commission is holding a virtual event and teleconference on SHINE Medical Technologies’ plans to license and operate a medical isotope production facility in Janesville, Wis. The online public meeting will be held on July 27 from 7:00 p.m. to 9 p.m. (EDT).

The NRC is also seeking the public’s views regarding the agency’s draft supplemental environmental impact statement for SHINE’s application for a license to operate the facility, particularly regarding the conclusion that the environmental impacts are not great enough to prevent the NRC from considering issuance of the license.

SHINE Europe, a nascent subsidiary of Wisconsin-based SHINE Technologies, announced Wednesday that it has secured funding to begin designing an advanced medical isotopes facility in Veendam, the Netherlands. The new facility will use the same fusion-based neutron generator system SHINE is employing at its Janesville, Wis., facility to produce medical isotopes, including molybdenum-99, which is used in diagnostic imaging.

From the time we discovered how the sun produces energy, we have been captivated by the prospect of powering our society using the same principles of nuclear fusion. Fusion energy promises the bounty of electricity we need to live our lives without the pollution inherent in fossil fuels, such as oil, gas, and coal. In addition, fusion energy is free from the stigma that has long plagued nuclear power about the storage and handling of long-lived radioactive waste products, a stigma from which fission power is only just starting to recover in green energy circles.

The Department of Energy’s National Nuclear Security Administration has issued a cooperative agreement worth $35 million to SHINE Technologies, based in Janesville, Wis., to support the commercial production of molybdenum-99, a critical isotope used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.

SHINE Medical Technologies plans to locate its European medical isotope production facility in the Netherlands after a yearlong search and a review of more than 50 proposals from sites across Europe. The company announced on May 20 that construction at the site should begin in 2023 with commercial production starting in late 2025.

The Nuclear Regulatory Commission has approved a request by SHINE Medical Technologies for an exemption from regulations on how commercial grade equipment is defined, allowing the company to more easily procure components for the medical isotope production facility it is building in Janesville, Wis.

Completing a 5,700-mile journey from Belgium, two 24-ton particle accelerators were delivered to NorthStar Medical Radioisotopes’ facility in Beloit, Wis., on April 22, the Wisconsin State Journal reported. Photos and a video of the accelerators being received at the facility are included in the report.